Danish biopharmaceutical company Genmab presents new data from the Phase 1/2 RAINFOL-01 study, in which the drug rinatabart sesutecan (Rina-S) shows a confirmed objective response rate of 50 percent in patients with advanced uterine cancer who have previously been treated with both platinum-based chemotherapy and immunotherapy.

Two complete responses were observed, and the median duration of treatment response had not yet been reached at 7.7 months of follow-up. The results were presented at this year's ASCO meeting. The Phase 2 study is ongoing and a Phase 3 study is planned. Side effects were mostly manageable, and no signs of eye or lung toxicity were noted, which are often seen with similar drugs.

"Rina-S represents the type of innovation that defines our focus at Genmab, which is to develop wholly owned, novel antibody-based medicines that have the potential to transform cancer treatment and address a significant unmet need, including for patients with advanced endometrial cancer," said Judith Klimovsky, M.D., Executive Vice President and Chief Development Officer at Genmab.

"The encouraging early signals in endometrial cancer underscore our deep commitment to making a meaningful impact for women with gynecological cancers, where treatment advances have long lagged behind the need," she continued.